VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ELAN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ELANElanco Animal Health Incorporated
$26.70$13.3B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
ELAN logo

Elanco Animal Health Incorporated

ELAN
NYSE · Specialty & Generic Drugs
$26.70
At close - Nov 18, 4:00 PM EST - USD
Market Cap$13.34B
P/E-92.0x
52W High$27.98
Volume5.76M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Deleveraging Progress Offset by Persistent GAAP Losses

Elanco's total debt has fallen from $5.7B in 2024Q2 to $3.7B in 2026Q3, and its debt-to-equity ratio improved from 0.96 to 0.56, suggesting meaningful balance sheet repair is underway.

GrowthMixed
ProfitabilityStrained
ValuationExpensive
TechnicalsNeutral
Explore valuation models
MARKET ACTION

ELAN price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

10/12 Beats

EPS beat 10 of last 12 quarters

02

Valuation risk

-397% Peers

P/E is 397% below peer median

03

Market leadership

RS 82 · Leader

High momentum (Outperforming 82% of market)

04

Trend Check

N/A

Trend data unavailable

Next CatalystEstimated earnings · Feb 6
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue growth slowed to 11.3% in 2026Q3 while operating margin compressed to 6.4% from 22.4% in 2026Q1, suggesting operating income is not yet scaling with a gross margin that has recovered to roughly 57%.

Analyst Consensus-0.1% target
Buy(22 analysts)
15 Buy5 Hold2 Sell

The Bull Case

Upside Catalysts

Strong quarterly results

Elanco's latest quarterly results and initial 2026 guidance have improved investor sentiment, highlighting operational execution and margin expansion.

Market leadership position

Elanco is the second largest independent animal health player in a growing market, with a strong presence in both farm animals and pets.

Innovative product pipeline

The company has a late-stage pipeline with potential blockbuster products expected to launch in large market spaces, driving future growth.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
ELAN+18.56%
S&P 500 (^GSPC)+6.88%
1-Year Return
ELAN+24.82%
S&P 500 (^GSPC)+10.62%
3-Year Return
ELAN+124.75%
S&P 500 (^GSPC)+65.68%
5-Year Return
ELAN-17.44%
S&P 500 (^GSPC)+58.23%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
-92.0x
Forward P/E
23.6x
EV/EBITDA80th %ile
16.2x
FCF YieldCash Flow
3.1%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-92.0x
17.8x
0th· Low
EV/EBITDA
16.2x
12.5x
80th· High
Price/FCF
32.7x
39.6x
40th· Fair
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$13.22-50.5%
Base (Fair)$24.35-9.1%
Bull$37.18+39.3%
$13.22 Bear$24.35 Base$37.18 Bull
Current Market Price: $26.70
Trades at a 9.7% premium to Base DCF ($24.35)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$4.71B+6.2% YoY
Net income FY25
-$232M-168.6% YoY
Free cash flow FY25
$284M-27.9% YoY
Operating margin FY25
5.3%-0.3 pts YoY
ROIC (FY25)1.9%
Avg ROIC 5Y1.9%
ROE (TTM)-2.2%
Piotroski Score6 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate10/12 (83%)
Revenue Beat Rate11/12 (92%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 6, 2026
$0.27+33.1%
vs $0.20
$1.3B+4.7%
vs $1.2B
Q3 2026
Aug 5, 2026
$0.34+26.3%
vs $0.27
$1.4B+4.2%
vs $1.3B
Q2 2026
May 6, 2026
$0.40+15.7%
vs $0.35
$1.4B+7.4%
vs $1.3B
Q1 2026
Feb 24, 2026
$0.13+18.2%
vs $0.11
$1.1B+4.7%
vs $1.1B
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·Nov 9, 2026
Elanco Animal Health Incorporated (ELAN) Presents at 2026 UBS Global Healthcare Conference Transcript

Elanco Animal Health Incorporated ( ELAN ) 2026 UBS Global Healthcare Conference November 9, 2026 1:15 PM EST Company Participants Robert VanHimbergen - Executive VP & CFO Rajeev Modi - Executive Vice President of U.S. Pet Health & Global Digital Transformation Conference Call Participants Andrea Zayco Narvaez Alfonso - UBS Investment Bank, Research Division Presentation Andrea Zayco Narvaez Alfonso UBS Investment Bank, Research Division So good afternoon, everybody. I'm Andrea Alfonso.

The Motley Fool·Nov 9, 2026
Elanco Animal Health: 3 Key Takeaways for Long-Term Investors

Third-quarter organic constant currency revenue grew 9% year over year. Elanco Animal Health lowered gross debt by $216 million in Q3.

MarketBeat·Nov 7, 2026
Elanco Animal Health Q3 Earnings Call Highlights

Elanco Animal Health NYSE: ELAN raised its full-year outlook after third-quarter revenue rose 11%, driven by demand for its pet health products Zenrelia and Credelio Quattro and higher prices across its portfolio.

Seeking Alpha·Nov 6, 2026
Elanco Animal Health Incorporated (ELAN) Q3 2026 Earnings Call Transcript

Elanco Animal Health Incorporated ( ELAN ) Q3 2026 Earnings Call November 6, 2026 8:00 AM EST Company Participants Tiffany Kanaga - VP of Investor Relations & ESG Jeffrey Simmons - President, CEO & Director Robert VanHimbergen - Executive VP & CFO Conference Call Participants Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Glen Santangelo - Barclays Bank PLC, Research Division Matthew Dellatorre - Goldman Sachs Group, Inc., Research Division Erin Wilson Wright - Morgan Stanley, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Andrea Zayco Narvaez Alfonso - UBS Investment Bank, Research Division Navann Ty Dietschi - BNP Paribas, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Steven Dechert - KeyBanc Capital Markets Inc., Research Division Christopher LoBianco - TD Cowen, Research Division Presentation Operator Good day, and welcome to Elanco Animal Health Reports Third Quarter 2026 Results.

Filtered for Elanco Animal Health IncorporatedMore Headlines
04

Compare before deciding

Benchmark ELAN against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Elanco Animal Health Incorporated (ELAN)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ELAN logoELANElanco Animal Health IncorporatedCurrent
$26.70$13.34B-92.016.22%-2.86%-2.24%—
ZTS logoZTSZoetis Inc.
$85.55$35.86B14.162.28%26.15%76.4%2.34%
PCRX logoPCRXPacira BioSciences, Inc.
$36.48$1.43B39.483.63%5.08%5.53%—
PAHC logoPAHCPhibro Animal Health Corporation
$35.57$1.44B14.1817.12%6.67%27.44%1.33%
NEOG logoNEOGNeogen Corporation
$11.08$2.41B-43.06-2.71%-6.35%-2.68%—
PETS logoPETSPetMed Express, Inc.
$0.90$19.26M-0.70-21.13%-16.97%-107.1%0.11%

Compare ELAN vs Peers

Elanco Animal Health Incorporated (ELAN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ZTS

Most directly comparable listed peer for ELAN.

Scale Benchmark

vs LLY

Larger-name benchmark to compare ELAN against a more recognizable public peer.

Peer Set

Compare Top 5

vs ZTS, PCRX, PAHC, NEOG

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

ELAN SEC Filings & Documents

Elanco Animal Health Incorporated (ELAN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 6, 2026·SEC

Material company update

Aug 5, 2026·SEC

Material company update

May 27, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 24, 2026·SEC

FY 2025

Feb 25, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 6, 2026·SEC

FY 2026

Aug 5, 2026·SEC

FY 2026

May 6, 2026·SEC

Get notified when ELAN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ELAN Frequently Asked Questions

Elanco Animal Health Incorporated (ELAN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Elanco Animal Health Incorporated's revenue?

Elanco Animal Health Incorporated (ELAN) reported $5.15B in revenue over the trailing twelve months. Revenue was $4.71B in fiscal year 2025. That is 62% more than the $2.91B of fiscal year 2016.

How fast is Elanco Animal Health Incorporated growing?

Elanco Animal Health Incorporated (ELAN) grew revenue by 12.1% over the trailing twelve months, compared with the twelve months before.

Is ELAN profitable?

No. Elanco Animal Health Incorporated (ELAN) reported a net loss of $147.0M over the trailing twelve months.

Dividend & Returns
What is ELAN's return on equity?

Elanco Animal Health Incorporated (ELAN) had a return on equity (ROE) of -2.2% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Elanco Animal Health Incorporated's free cash flow?

Elanco Animal Health Incorporated (ELAN) generated $408.0M in free cash flow over the trailing twelve months.

What if you invested $1,000 in ELAN back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →